A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : 1,5-AG / 1,5-anhydroglucitol

[Related PubMed/MEDLINE]
Total Number of Papers: 143
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   1,5-AG  (>> Co-occurring Abbreviation)
Long Form:   1,5-anhydroglucitol
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2016 1,5-Anhydro-D-Glucitol Could Reflect Hypoglycemia Risk in Patients with Type 2 Diabetes Receiving Insulin Therapy. CGMS, T2DM
2016 Alcohol consumption reduces HbA1c and glycated albumin concentrations but not 1,5-anhydroglucitol. FPG, GA
2016 Alternate glycemic markers reflect glycemic variability in continuous glucose monitoring in youth with prediabetes and type 2 diabetes. CGM, FA, FPG, GA, HbA1c, MAGE, SD, T2D
2016 Association of 1,5-Anhydroglucitol With Cardiovascular Disease and Mortality. ARIC
2016 Association of a Biomarker of Glucose Peaks, 1,5-Anhydroglucitol, With Subclinical Cardiovascular Disease. ARIC, CIMT, hs-cTnT
2016 Association of CD34/CD133/VEGFR2-Positive Cell Numbers with Eicosapentaenoic Acid and Postprandial Hyperglycemia in Patients with Coronary Artery Disease. AA, BMI, CAD, CI, DM, EPA, EPCs
2016 Do glycemic marker levels vary by race? Differing results from a cross-sectional analysis of individuals with and without diagnosed diabetes. ---
2016 Effect of renal function on serum concentration of 1,5-anhydroglucitol in type 2 diabetic patients in chronic kidney disease stages I-III: A comparative study with HbA1c and glycated albumin. A1M, eGFR, GA
2016 Glycemic control and variability in association with body mass index and body composition over 18months in youth with type 1 diabetes. CGM, DXA
10  2016 Impact of serum 1,5-anhydro-d-glucitol level on prediction of major adverse cardiac and cerebrovascular events in non-diabetic patients without coronary artery disease. DM, MACCE
11  2016 Low and exacerbated levels of 1,5-anhydroglucitol are associated with cardiovascular events in patients after first-time elective percutaneous coronary intervention. FBS, PCI
12  2016 Lower 1,5-anhydroglucitol is associated with adverse clinical events after percutaneous coronary intervention. CAD, Hb, PCI, TLR
13  2016 Measurement of 1,5-anhydroglucitol in blood and saliva: from non-targeted metabolomics to biochemical assay. ---
14  2016 Measurement of Postmortem 1,5-anhydroglucitol in Vitreous Humor for Forensic Diagnosis. CSF
15  2016 Racial Differences in and Prognostic Value of Biomarkers of Hyperglycemia. ARIC, CVD, ESRD
16  2016 Screening for type 2 diabetes and prediabetes in obese youth: evaluating alternate markers of glycemia - 1,5-anhydroglucitol, fructosamine, and glycated albumin. 2hG, BMI, FA, GA, HbA1c, OGTT, ROC, ROC-AUCs
17  2016 Serum 1,5-anhydroglucitol level as a screening tool for diabetes mellitus in a community-based population at high risk of diabetes. AUCs, FBG, HbA1c, PBG, ROC
18  2016 The establishment of biological reference intervals of nontraditional glycemic markers in a Chinese population. FA, GA
19  2015 1,5-ANHYDROGLUCITOL AND NEONATAL COMPLICATIONS IN PREGNANCY COMPLICATED BY DIABETES. BMI, NBW, T1DM, T2DM
20  2015 1,5-anhydroglucitol as a useful marker for assessing short-term glycemic excursions in type 1 diabetes. CGMS, HbA1c, MAGE, SD
21  2015 Ability of 1,5-Anhydro-d-glucitol Values to Predict Coronary Artery Disease in a Non-Diabetic Population. CAD, HbA1c
22  2015 Alternative biomarkers for assessing glycemic control in diabetes: fructosamine, glycated albumin, and 1,5-anhydroglucitol. GA
23  2015 Association of cerebral white matter lesions with cognitive function and mood in Japanese elderly people: a population-based study. BP, DWMH, LDL-C, PVH, WMLs
24  2015 Association of hemoglobin A1c and glycated albumin with carotid atherosclerosis in community-dwelling Japanese subjects: the Hisayama Study. FPG, GA, GI, HbA1c, IMT, PG
25  2015 Comparison of the administration of teneligliptin every day versus every other day in Japanese patients with type 2 diabetes: a randomized non-inferior test. GA
26  2015 Glycated albumin is more closely correlated with coronary artery disease than 1,5-anhydroglucitol and glycated hemoglobin A1c. CAD, CSI, GA, HbA1c
27  2015 HOMA-IR Values are Associated With Glycemic Control in Japanese Subjects Without Diabetes or Obesity: The KOBE Study. FPG, HOMA-IR
28  2015 Lower 1,5-anhydroglucitol is associated with denovo coronary artery disease in patients at high cardiovascular risk. CAD, HbA1c
29  2015 Rational diagnoses of diabetes: the comparison of 1,5-anhydroglucitol with other glycemic markers. DM, FPG, ROC
30  2015 Reactivity of sorbose dehydrogenase from Sinorhizobium sp. 97507 for 1,5-anhydro-D-glucitol. ---
31  2015 Salivary protein glycosylation as a noninvasive biomarker for assessment of glycemia. CGM, HbA1c
32  2015 Value of serum 1,5-anhydroglucitol measurements in childhood obesity in the continuum of diabetes. T2DM
33  2015 [THE DIFFERENCES OF TREC (T-CELL RECEPTOR EXCISION CIRCLES) CONCENTRATION IN TYPE 2 DIABETIC PATIENTS]. ---
34  2014 1,5-Anhydro-D-glucitol predicts coronary artery disease prevalence and complexity. CAD, HbA1c
35  2014 1,5-Anhydroglucitol and glycated albumin in glycemia. GA
36  2014 1,5-Anhydroglucitol in saliva is a noninvasive marker of short-term glycemic control. ---
37  2014 Add-on treatment with teneligliptin ameliorates glucose fluctuations and improves glycemic control index in Japanese patients with type 2 diabetes on insulin therapy. CGM, GA, hs-CRP
38  2014 Association of 1,5-anhydroglucitol with diabetes and microvascular conditions. ARIC, HR, OR
39  2014 Association of reduced levels of serum 1,5-Anhydro-d-glucitol with carotid atherosclerosis in patients with type 2 diabetes. IMT, PS
40  2014 Beyond HbA1c and glucose: the role of nontraditional glycemic markers in diabetes diagnosis, prognosis, and management. HbA1c
41  2014 Change in urinary N-acetyl-beta-d-glucosaminidase levels relevant to postprandial glycemic control conditions in subjects without diabetes mellitus. DM
42  2014 Comparative associations of diabetes risk factors with five measures of hyperglycemia. ARIC, BMI, HbA1c
43  2014 Effect of repaglinide, administered two or three times daily for 3 months, on glycaemic control in Japanese patients with type 2 diabetes mellitus. GA
44  2014 Effect of sitagliptin on glycemic control and beta cell function in Japanese patients given basal-supported oral therapy for type 2 diabetes. AUC-PG, BOT, DPP-4i, GA, PG, PI, T2DM
45  2014 Increased circulating RANTES in type 2 diabetes. ---
46  2014 Long-term Effects of Mitiglinide in Japanese Diabetics Inadequately Controlled with DPP-4 Inhibitor or Biguanide Monotherapy. DPP-4, DPP-4 inhibitor CTG, PPG, T2DM
47  2014 Low levels of 1,5-anhydro-D-glucitol are associated with vascular endothelial dysfunction in type 2 diabetes. CGM, L_RHI, RHI, T2DM
48  2014 Postprandial glycemic control conditions in relation to urinary N-acetyl-beta-D-glucosaminidase in patients with type 2 diabetes mellitus without low glomerular filtration rate. HbA1c, NAG
49  2014 The use of 1.5-anhydroglucitol for monitoring glycemic control in islet transplant recipients. ICT
50  2014 Thresholds of various glycemic measures for diagnosing diabetes based on prevalence of retinopathy in community-dwelling Japanese subjects: the Hisayama Study. AUC, DR, FPG, GA, HbA1c, PG, ROC
51  2014 [Indicators of glycemic control --hemoglobin A1c (HbA1c), glycated albumin (GA), and 1,5-anhydroglucitol (1,5-AG)]. AG, GA, NGSP
52  2013 1,5-Anhydroglucitol as a marker of maternal glycaemic control and predictor of neonatal birthweight in pregnancies complicated by type 1 diabetes mellitus. CGMS, ROC
53  2013 1,5-Anhydroglucitol in diabetes mellitus. ---
54  2013 Efficacy and safety of sitagliptin as add-on therapy on glycemic control and blood glucose fluctuation in Japanese type 2 diabetes subjects ongoing with multiple daily insulin injections therapy. BMI, MAGE, MDI, SMPG
55  2013 Evaluation of 1,5-anhydroglucitol as a marker for glycemic variability in patients with type 2 diabetes mellitus. 8-isoPGF2alpha, AUC-180, CGMS, CONGA, MAGE, MODD, MPMG
56  2013 Evaluation of glycemic variability in well-controlled type 2 diabetes mellitus. AUC-180, CGMS, FA, HbA1c, MAGE, MAGEgos, MPMG
57  2013 Glycemic variability is an independent predictive factor for development of hepatic fibrosis in nonalcoholic fatty liver disease. 75-g OGTT, CGMS, NAFLD, NASH, T2DM
58  2013 Protective effects of dietary 1,5-anhydro-D-glucitol as a blood glucose regulator in diabetes and metabolic syndrome. ---
59  2013 Relationship between postprandial glucose level and carotid artery stiffness in patients without diabetes or cardiovascular disease. IMT, PI
60  2013 Serum uric acid in relation to serum 1,5-anhydroglucitol levels in patients with and without type 2 diabetes mellitus. DM, UA
61  2012 A study on the association of serum 1,5-anhydroglucitol levels and the hyperglycaemic excursions as measured by continuous glucose monitoring system among people with type 2 diabetes in China. ---
62  2012 Alternative markers of hyperglycemia and risk of diabetes. A1C, ARIC, HR
63  2012 Associations of alternative markers of glycemia with hemoglobin A(1c) and fasting glucose. AUC
64  2012 Clinical and forensic examinations of glycemic marker 1,5-anhydroglucitol by means of high performance liquid chromatography tandem mass spectrometry. ---
65  2012 Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study). AOC, AUC, BNP, CGM, CPR, GA, IRI, MAGE, PAI-1
66  2012 Effects of bile-acid-binding resin (colestimide) on blood glucose and visceral fat in Japanese patients with type 2 diabetes mellitus and hypercholesterolemia: an open-label, randomized, case-control, crossover study. T2D, VFA
67  2012 Evaluation of 1,5-anhydroglucitol, hemoglobin A1c, and glucose levels in youth and young adults with type 1 diabetes and healthy controls. HbA1c, T1D
68  2012 Increased 1,5-anhydroglucitol predicts glycemic remission in patients with newly diagnosed type 2 diabetes treated with short-term intensive insulin therapy. CI, CSII, FA
69  2012 Pilot Study of Caffeine Abstinence for Control of Chronic Glucose in Type 2 Diabetes. HbA1c
70  2012 Serum 1,5-anhydroglucitol is associated with diabetic retinopathy in Type 2 diabetes. SMC-DPP
71  2011 1,5-Anhydroglucitol levels are low irrespective of plasma glucose levels in patients with chronic liver disease. CLD
72  2011 A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers. CGM, DPP-4, GIP, GLP-1
73  2011 Comparison of efficacy of concomitant administration of mitiglinide with voglibose and double dose of mitiglinide in patients with type 2 diabetes mellitus. GLP-1, OHA
74  2011 Correlation between 1,5-anhydroglucitol and glycemic excursions in type 2 diabetic patients. CGMS, FBG, GA, HbA1c, iAUC, LAGE, MAGE, MBG, MODD, PPGE, SDBG
75  2011 Correlation between baseline serum 1,5-anhydroglucitol levels and 2-hour post-challenge glucose levels during oral glucose tolerance tests. 2-h PG, min, OGTTs, ROC
76  2011 Evaluation of serum and urine 1,5-anhydro-D-glucitol and myo-inositol concentrations in healthy dogs. mI
77  2011 Improvement of postprandial hyperglycemia and arterial stiffness upon switching from premixed human insulin 30/70 to biphasic insulin aspart 30/70. BIAsp 30, CAVI
78  2011 Nontraditional markers of glycemia: associations with microvascular conditions. ARIC
79  2011 Selective contribution of waist circumference reduction on the improvement of sleep-disordered breathing in patients hospitalized with type 2 diabetes mellitus. AHI, BMI, hs-CRP, SDB, T2DM, TBARS, WC
80  2011 Serum 1,5-anhydro-D-glucitol levels predict first-ever cardiovascular disease: an 11-year population-based cohort study in Japan, the Suita study. CHD, CVD, HRs
81  2011 The interrelationships of glycemic control measures: HbA1c, glycated albumin, fructosamine, 1,5-anhydroglucitrol, and continuous glucose monitoring. AUC, CGM, HbA1c
82  2011 [Development of the novel delivery system of GLP-1 administration for the treatment of diabetes mellitus]. GLP-1
83  2010 1,5-Anhydroglucitol attenuates cytokine release and protects mice with type 2 diabetes from inflammatory reactions. IL, iNOS, LPS, MCP, TNF
84  2010 Habitual intake of dairy products influences serum 1,5-anhydroglucitol levels independently of plasma glucose. ---
85  2010 Lack of correlation between 1,5-anhydroglucitol assay and oral glucose tolerance test in patients with cystic fibrosis. CFRD, IGT, OGTT
86  2010 Relationship between clinical markers of glycemia and glucose excursion evaluated by continuous glucose monitoring (CGM). AG, CGM, CV, GA, SD
87  2010 Serum 1,5-anhydroglucitol levels in patients with fulminant type 1 diabetes are lower than those in patients with type 2 diabetes. FT1DM, T2DM
88  2009 Assessing postprandial glucose using 1,5-anhydroglucitol: An integrative literature review. PPHG
89  2009 Close relationship between serum concentrations of 1,5-anhydroglucitol and uric acid in non-diabetic male subjects implies common renal transport system. ---
90  2009 Racial and ethnic differences in mean plasma glucose, hemoglobin A1c, and 1,5-anhydroglucitol in over 2000 patients with type 2 diabetes. A1C, MPG
91  2008 1,5-anhydroglucitol (GlycoMark) as a marker of short-term glycemic control and glycemic excursions. ---
92  2008 A novel fully enzymatic method for determining glucose and 1,5-anhydro-D-glucitol in serum of one cuvette. GK
93  2008 Association of 1,5-anhydroglucitol and 2-h postprandial blood glucose in type 2 diabetic patients. ---
94  2008 Clinical application of 1,5-anhydroglucitol measurements in patients with hepatocyte nuclear factor-1alpha maturity-onset diabetes of the young. HNF-1alpha, MODY, ROC
95  2008 Comparison of pre- vs. postmeal administration of miglitol for 3 months in type 2 diabetic patients. alphaGIs
96  2008 Comparison of twice-daily injections of biphasic insulin lispro and basal-bolus therapy: glycaemic control and quality-of-life of insulin-naive type 2 diabetic patients. BB, BMI, ITR-QOL, QOL
97  2008 Determination of glycemic monitoring marker 1,5-anhydroglucitol in plasma by liquid chromatography-electrospray tandem mass spectrometry. ---
98  2008 Does serum 1,5-anhydroglucitol establish a relationship between improvements in HbA1c and postprandial glucose excursions? Supportive evidence utilizing the differential effects between biphasic insulin aspart 30 and insulin glargine. BIAsp 30, IGlar, PPG
99  2007 Hyperglycemia and diabetic renal change in a model of polyvinyl alcohol bioartificial pancreas transplantation. ---
100  2007 Pro-atherogenic alterations in T-lymphocyte subpopulations related to acute hyperglycaemia in type 2 diabetic patients. DM